Orabloc Articaine HCI 4% & Epinephrine Anesthetic, 1:200,000, 1.8mL, 50 /bx 2101052

Product Description

Orabloc® is an aseptically manufactured Articaine with epinephrine based dental anesthetic. It has a rapid onset of anesthesia within 1-9 minutes for fast, effective anesthesia. Complete anesthesia lasts about 1 hour for infiltration, up to 2 hours for nerve block. Latex free and lubricated rubber closures for maximum safety, smooth plunger movement and precise control during injection. Orabloc® is the only aseptically manufactured articaine in the US Rapid onset of anesthesia within 1-9 minutes Complete anesthesia lasts about 1 hour for infiltration, up to 2 hours for nerve block Most common adverse reactions (incidence >2%) are headache and pain 10% overage of epinephrine(1) 24 month shelf life when stored at room temperature Sodium edetate free, methylparaben free and latex free Each Orabloc® individual cartridge is blister packed for maximum protection during storage and handling

Orabloc Articaine HCI 4% & Epinephrine Anesthetic, 1:200,000, 1.8mL, 50 /bx

Orabloc® is an amide local anesthetic containing a vasoconstrictor indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental sodium metabisulfite. Orabloc® is contraindicated in patients who are hypersensitive to products containing sulfites. Products containing sulfites may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Reactions to Orabloc® (pain and headache, for example, or convulsions or respiratory arrest following accidental intravascular injection) are characteristic of those associated with other amide-type local anaesthetics. Accidental intravascular injection may be associated with convulsion, followed by central nervous system or cardio-respiratory depression and coma, progressing ultimately to respiratory arrest. Dental practitioners and/or clinicians who employ local anaesthetic agents should be well versed in diagnosis and management of emergencies that may arise from their use. Administration of Orabloc® results in a 3 to 5 fold increase in plasma epinephrine concentrations compared to baseline; however, in healthy adults it does not appear to be associated with marked increases in blood pressure or heart rate, except in the case of accidental intravascular injection. Inform patients in advance of the possibility of temporary loss of sensation and muscle function following infiltration and nerve block injections. Instruct patients not to eat or drink until normal sensation returns.